DRUG (Bright Minds Biosciences) Other Current Receivables: $0.83 Mil (As of Mar. 2026)


DRUG Bright Minds Biosciences Inc DRUG
34 GF Score
Price $67.68
! 2 Warning Signs
View Full Analysis

What is Bright Minds Biosciences Other Current Receivables?

Bright Minds Biosciences DRUG +1.59% 34 Other Current Receivables is $0.83 Mil as of Mar. 2026. GuruFocus rates DRUG with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Bright Minds Biosciences's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.83 Mil.

Bright Minds Biosciences's quarterly Other Current Receivables increased from Sep. 2025 ($0.30 Mil) to Dec. 2025 ($0.37 Mil) and increased from Dec. 2025 ($0.37 Mil) to Mar. 2026 ($0.83 Mil).

Bright Minds Biosciences's annual Other Current Receivables increased from Sep. 2023 ($0.03 Mil) to Sep. 2024 ($0.04 Mil) and increased from Sep. 2024 ($0.04 Mil) to Sep. 2025 ($0.30 Mil).

Bright Minds Biosciences Other Current Receivables Related Terms

Bright Minds Biosciences Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Bright Minds Biosciences's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bright Minds Biosciences Other Current Receivables Chart

Bright Minds Biosciences Annual Data
Trend Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Other Current Receivables
Get a 7-Day Free Trial 0.09 0.12 0.03 0.04 0.30

Bright Minds Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.20 0.30 0.37 0.83
DRUG
34GF Score
Bright Minds Biosciences Inc DRUG
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bright Minds Biosciences Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.83 Mil mean?
Bright Minds Biosciences (DRUG) has a Other Current Receivables of $0.83 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bright Minds Biosciences and its competitors.
Is Bright Minds Biosciences' Other Current Receivables too high?
Bright Minds Biosciences' current Other Current Receivables is $0.83 Mil. Overall, Bright Minds Biosciences has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Bright Minds Biosciences' Other Current Receivables compare to VRTX and REGN?
Bright Minds Biosciences' Other Current Receivables of $0.83 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Bright Minds Biosciences and its competitors. Bright Minds Biosciences's current Other Current Receivables is $0.83 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bright Minds Biosciences stock overvalued right now?
Bright Minds Biosciences (DRUG) has a current Other Current Receivables of $0.83 Mil. The current Other Current Receivables is $0.83 Mil. Bright Minds Biosciences' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Bright Minds Biosciences (DRUG), the current Other Current Receivables is $0.83 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bright Minds Biosciences Business Description

Other Exchanges DRUG:Canada
Address 19 Vestry Street, New York, NY, USA, 10013
Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
34GF Score

Get the complete analysis for DRUG

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$67.68
Price